rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    OGN
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Organon & Co stock hits 52-week high at 13.91 USD
      9h agoInvesting.comOGN
      Sun Pharma seeks $4 bln loan to refinance Organon deal- ET
      Nov 16Investing.comOGN
      how InvestingPro’s fair value spotted Organon’s 72% healthcare gain By Investing.com
      Nov 11Investing.comOGN
      Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
      Nov 10Yahoo FinanceOGN
      Organon Co earnings missed by $0.34, revenue was in line with estimates
      Nov 10Investing.comOGN
      Organon earnings on deck as Sun Pharma merger awaits approval
      Nov 8Investing.comOGN
      Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting
      Nov 5Yahoo FinanceOGN
      Organon (OGN) Q3 Results Highlight A Thin Margin Cushion
      Nov 1Yahoo FinanceOGN
      Organon declares $0.02 quarterly dividend payable in December
      Oct 30Investing.comOGN
      Organon (OGN) Q3 Earnings and Revenues Top Estimates
      Oct 30Yahoo FinanceOGN
      Organon: Q3 Earnings Snapshot
      Oct 30Yahoo FinanceOGN
      Sun Pharma's profit falls on Organon deal charge; specialty drug sales remain strong
      Oct 30ReutersOGN
      India's Sun Pharma posts lower quarterly profit on one-time acquisition-related charge
      Oct 30Yahoo FinanceOGN
      Organon & Co stock hits 52-week high at 13.83 USD
      Oct 29Investing.comOGN
      Organon set to report earnings ahead of Sun Pharma merger
      Oct 28Investing.comOGN
      Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It

      Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

      Oct 26Yahoo FinanceOGN
      Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
      Oct 19Yahoo FinanceOGN
      Organon presents 6-year data for hormone-free IUD MIUDELLA
      Oct 16Investing.comOGN
      Organon Says 6-Year Miudella Data Supports FDA Application for Extended Use
      Oct 16Yahoo FinanceOGN
      Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
      Oct 14Yahoo FinanceOGN
      Organon & Co stock hits 52-week high at 13.79 USD
      Oct 7Investing.comOGN
      Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
      Oct 2Yahoo FinanceOGN
      Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference

      JERSEY CITY, N.J., October 01, 2026--Organon to unveil first large-scale real-world effectiveness analyses of VTAMA (tapinarof) cream, 1% in patients with eczema at Fall Clinical.

      Oct 1Yahoo FinanceOGN
      Organon Says Nduvra Cream Gets Canada Approval for Atopic Dermatitis
      Sep 28Yahoo FinanceOGN
      Why Organon (OGN) Is Getting Attention Today

      Why MIUDELLA’s FDA review matters for Organon stock Organon (OGN) just picked up fresh attention after the FDA accepted a supplemental application to extend use of MIUDELLA, a copper IUD that Organon licensed globally earlier this year. The device is already indicated for pregnancy prevention for up to 3 years, with an extended duration review underway and commercial availability targeted for late 2026. For investors watching Organon stock, this product sits squarely in the women’s health...

      Sep 22Yahoo FinanceOGN
      Organon (OGN) Wins FDA Review Acceptance For Its Hormone Free Contraceptive Device

      Organon (NYSE: OGN) received FDA acceptance to review a supplemental New Drug Application for its hormone free contraceptive device MIUDELLA. The company entered an exclusive global licensing agreement for MIUDELLA, aiming to expand access to hormone free contraception across markets. Organon plans commercial availability of MIUDELLA as a longer duration contraceptive option, subject to regulatory review outcomes and launch execution. Beyond the MIUDELLA sNDA review and new global license,...

      Sep 22Yahoo FinanceOGN
      how InvestingPro spotted Organon’s 65% gain in healthcare sector By Investing.com
      Sep 17Investing.comOGN
      Organon Says Application to Extend Miudella IUD Use to Six Years Accepted by FDA for Review

      Organon (OGN) said Monday the US Food and Drug Administration has accepted for review a supplemental

      Sep 14Yahoo FinanceOGN
      Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device
      Sep 14Yahoo FinanceOGN
      Organon Stock: A Merger-Arbitrage Hold With Limited Upside (NYSE:OGN)
      Sep 12Seeking AlphaOGN
      Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
      Sep 8Yahoo FinanceOGN
      Organon & Co stock hits 52-week high at $13.78
      Sep 1Investing.comOGN
      Organon earnings up next: Can drugmaker rebound after Q1 miss?
      Aug 23Investing.comOGN

      This is the newest page. Registered accounts read further back.